Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
